Tracking China’s response to the coronavirus outbreak

Researchers are using advanced technology—including AI, natural language processing (NLP) and satellite imaging—to track how the new coronavirus has impacted China.

According to a new report from IEEE Spectrum, a private Chinese banking company found a way to use its own deep learning model to measure the area’s response to COVID-19. The algorithm can shine light on key economic factors—employee activity and so on—while also providing fresh insight into what might happen if the disease gets worse in other countries.

“The team used its neural network to analyze visible, near-infrared, and short-wave infrared images from various satellites, including the infrared bands from the Sentinel-2 satellite,” according to the report. “This allowed the system to look for hot spots indicative of actual steel manufacturing inside a plant. In the early days of the outbreak, this analysis showed that steel manufacturing had dropped to a low of 29% of capacity. But by Feb. 9, it had recovered to 76%.”

Researchers also estimated that about 75% of the Chinese workforce had returned to work by Marc 10. And NLP was used to explore social media outlets and other key online resources, finding that telecommuting for work was up 537% since Jan. 1 and online education is up 169%.

Click below to read the full story rom IEEE Spectrum:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.